S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
S&P 500   4,282.37 (+1.45%)
DOW   33,762.76 (+2.12%)
QQQ   354.65 (+0.75%)
AAPL   180.95 (+0.48%)
MSFT   335.40 (+0.85%)
META   272.61 (+0.00%)
GOOGL   124.67 (+0.77%)
AMZN   124.25 (+1.21%)
TSLA   213.97 (+3.11%)
NVDA   393.27 (-1.11%)
NIO   7.56 (+0.27%)
BABA   84.26 (+1.52%)
AMD   117.86 (-1.35%)
T   15.21 (-3.86%)
F   12.38 (+2.23%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.20%)
GE   105.79 (+1.07%)
DIS   90.77 (+2.46%)
AMC   4.56 (+0.00%)
PFE   38.35 (+0.87%)
PYPL   63.96 (+1.44%)
NFLX   400.47 (-0.66%)
NASDAQ:SLN

Silence Therapeutics (SLN) Stock Forecast, Price & News

$5.40
-0.31 (-5.43%)
(As of 06/2/2023 ET)
Compare
Today's Range
$5.20
$5.81
50-Day Range
$4.61
$9.19
52-Week Range
$4.55
$17.99
Volume
34,884 shs
Average Volume
60,763 shs
Market Capitalization
$161.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.75

Silence Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
728.7% Upside
$44.75 Price Target
Short Interest
Healthy
0.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.83) to ($1.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

449th out of 983 stocks

Pharmaceutical Preparations Industry

215th out of 486 stocks


SLN stock logo

About Silence Therapeutics (NASDAQ:SLN) Stock

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
SLN Silence Therapeutics plc
See More Headlines

SLN Price History

SLN Company Calendar

Last Earnings
3/15/2023
Today
6/02/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SLN
Fax
N/A
Employees
105
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$44.75
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+728.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-50,080,000.00
Net Margins
-185.71%
Pretax Margin
-218.65%

Debt

Sales & Book Value

Annual Sales
$21.65 million
Book Value
$0.67 per share

Miscellaneous

Free Float
29,045,000
Market Cap
$161.62 million
Optionable
Not Optionable
Beta
0.74

Social Links


Key Executives

  • Mr. Craig A. Tooman M.B.A. (Age 56)
    MBA, Pres, CEO & Exec. Director
    Comp: $481.48k
  • Ms. Rhonda L. Hellums (Age 50)
    Chief Financial Officer
    Comp: $270.1k
  • Dr. Giles V. Campion M.D. (Age 68)
    Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
    Comp: $617.91k
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corp. Communications
  • Dr. John Strafford Ph.D.
    Sr. VP of Bus. Devel., Alliance Management & New Product Devel.
  • Mr. Jørgen Wittendorff
    Sr. VP & Head of Manufacturing
  • Dr. Barbara A. Ruskin J.D. (Age 62)
    Ph.D., Sr. VP and Chief Intellectual Property & Innovation Officer
  • Dr. Eric Floyd Ph.D. (Age 60)
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Sr. VP & Head of Molecular Design













SLN Stock - Frequently Asked Questions

Should I buy or sell Silence Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SLN shares.
View SLN analyst ratings
or view top-rated stocks.

What is Silence Therapeutics' stock price forecast for 2023?

3 brokerages have issued twelve-month price objectives for Silence Therapeutics' shares. Their SLN share price forecasts range from $20.00 to $80.00. On average, they predict the company's share price to reach $44.75 in the next twelve months. This suggests a possible upside of 728.7% from the stock's current price.
View analysts price targets for SLN
or view top-rated stocks among Wall Street analysts.

How have SLN shares performed in 2023?

Silence Therapeutics' stock was trading at $15.25 at the start of the year. Since then, SLN stock has decreased by 64.6% and is now trading at $5.40.
View the best growth stocks for 2023 here
.

Are investors shorting Silence Therapeutics?

Silence Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 22,400 shares, a decline of 36.7% from the April 30th total of 35,400 shares. Based on an average trading volume of 74,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.1% of the shares of the stock are sold short.
View Silence Therapeutics' Short Interest
.

When is Silence Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SLN earnings forecast
.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (NASDAQ:SLN) announced its earnings results on Wednesday, March, 15th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by $0.91. The firm had revenue of $5.59 million for the quarter, compared to analyst estimates of $36.30 million. Silence Therapeutics had a negative net margin of 185.71% and a negative trailing twelve-month return on equity of 254.24%.

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the NASDAQ under the ticker symbol "SLN."

Who are Silence Therapeutics' major shareholders?

Silence Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include AXA S.A. (1.73%) and Schonfeld Strategic Advisors LLC (0.14%).

How do I buy shares of Silence Therapeutics?

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately $5.40.

How much money does Silence Therapeutics make?

Silence Therapeutics (NASDAQ:SLN) has a market capitalization of $161.62 million and generates $21.65 million in revenue each year. The company earns $-50,080,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Silence Therapeutics have?

The company employs 105 workers across the globe.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 HAMMERSMITH ROAD, LONDON X0, W14 8TH. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at 44-0-20-3457-6900.

This page (NASDAQ:SLN) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -